Summary
Dr S. John Wort is a HEFCE funded Clinical Senior Lecturer at the National Heart and Lung Institute, Imperial College London and Honorary Consultant at the Royal Brompton Hospital. His Clinical Specialities are Pulmonary Hypertension and Intensive Care Medicine. Dr Wort is Clinical Lead for Pulmonary Hypertension at the Royal Brompton Hospital, which is an NCG designated national centre for the treatment of pulmonary hypertension.
Dr Wort's first degree was in Chemistry, awarded from the University of Oxford (1988). He was awarded a university distinction in biochemistry and college exhibition in chemistry. He studied medicine at University College Hospitals and qualified in 1993. Dr Wort was awarded multiple pre-clinical and clinical prizes including the Meyerstein scholarship for best overall performance in BMS I and II, MacGrath prize in Medicine and John Briffa Prize for Outstanding Academic and Extra-curricular Activities. He gained his MRCP (Royal College of Physicians of London) in 1996, and was elected as a Fellow (FRCP) in 2010.
Dr Wort was awarded his PhD in 2002 which he undertook at Imperial College London, having been successfully awarded a Wellcome Trust Clinical Research Training Fellowship. He became a Consultant in 2006, qualifying in General Medicine, Respiratory Medicine and Intensive Care Medicine (CCST).
As a Clinical Senior Lecturer, Dr Wort splits his time between developing the Pulmonary Hypertension Service, being an Intensive Care physician and continuing his research interests. These are based around understanding the pathobiology of pulmonary vascular remodelling associated with the development of pulmonary arterial hypertension (PAH). This devastating disease affects young people predominantly, causing right ventricular failure and ultimately death. In particular, he is interested in the role of inflammation on pulmonary vascular remodelling, and the interactions of bone morphogenetic protein receptor II (BMPR II) on other relevant pathways such as the endothelin-1 axis. In addition, he is Principal Investigator for a national, multi-centred, DBPC study investigating the role of an endothelin receptor antagonist, bosentan, in the treatment of pulmonary hypertension associated with interstitial lung disease (B-PHIT-1).
Dr Wort sits on the committee of the National Pulmonary Hypertension physicians group, as well as the Advisory Boards of several Pharmaceutical companies, such as Pfizer and Bayer. He is on the Editorial board of the European Respiratory Review.
Finally, Dr Wort recently became a Fellow of The Faculty of Intensive Care Medicine.
Publications
Journals
Price LC, Kouranos V, Baughman R, et al., 2024, Use of pulmonary arterial hypertension therapies in patient swith sarcoidosis-associated pulmonary hypertension., Sarcoidosis Vasc Diffuse Lung Dis, Vol:41
Stubbs HD, Cannon J, Knightbridge E, et al., 2024, Sendaway capillary NT-proBNP in pulmonary hypertension., Bmj Open Respir Res, Vol:11
Piccari L, Wort SJ, 2024, Use of inhaled treprostinil in patients with interstitial lung disease and pulmonary hypertension: to boldly go where no other pulmonary vasodilator has gone before?, Thorax, Vol:79, Pages:295-296
Ulrich A, Wu Y, Draisma H, et al., 2024, Blood DNA methylation profiling identifies cathepsin Z dysregulation in pulmonary arterial hypertension, Nature Communications, Vol:15, ISSN:2041-1723
Shlobin OA, Shen E, Wort SJ, et al., 2024, Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension., Pulm Circ, Vol:14, ISSN:2045-8932